Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in InventoryChange in ReceivablesChange in Working CapitalDeferred TaxesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet Equity Issued and RepurchasedNet Income
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Cash from Financing Activities (2019 - 2025)

Historic Cash from Financing Activities for Sanofi (SNY) over the last 6 years, with Q4 2025 value amounting to -$9.6 billion.

  • Sanofi's Cash from Financing Activities fell 5514.27% to -$9.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$21.2 billion, marking a year-over-year decrease of 4388.53%. This contributed to the annual value of -$9.3 billion for FY2025, which is 4869.3% down from last year.
  • As of Q4 2025, Sanofi's Cash from Financing Activities stood at -$9.6 billion, which was down 5514.27% from -$6.6 billion recorded in Q3 2025.
  • Sanofi's 5-year Cash from Financing Activities high stood at $825.6 million for Q1 2024, and its period low was -$9.6 billion during Q4 2025.
  • Over the past 4 years, Sanofi's median Cash from Financing Activities value was -$4.4 billion (recorded in 2025), while the average stood at -$4.0 billion.
  • Per our database at Business Quant, Sanofi's Cash from Financing Activities skyrocketed by 40269.12% in 2021 and then plummeted by 51047.57% in 2025.
  • Sanofi's Cash from Financing Activities (Quarter) stood at $30.3 million in 2021, then crashed by 28677.94% to -$8.7 billion in 2023, then grew by 28.92% to -$6.2 billion in 2024, then tumbled by 55.14% to -$9.6 billion in 2025.
  • Its Cash from Financing Activities stands at -$9.6 billion for Q4 2025, versus -$6.6 billion for Q3 2025 and -$4.4 billion for Q2 2025.